TNFRSF17 and plasma cell myeloma: SG1-vcMMAF8 containing the drug monomethyl auristatin F (MMAF) was the first potent ADC targeting BCMA and demonstrated cytotoxic activity against BCMA-positive myeloma cell lines [109].